Recent investigations have centered on the convergence of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|GCGR agonist therapies and dopamine communication. While GCGR agonists are commonly employed for managing type 2 diabetes, their unexpected impacts on reinforcement circu